Yıl: 2021 Cilt: 36 Sayı: 2 Sayfa Aralığı: 236 - 246 Metin Dili: Türkçe DOI: 10.5505/tjo.2020.2579 İndeks Tarihi: 04-06-2022

Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer

Öz:
-
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Jeremic B, Dubinsky P, Filipovic N, Ozyigit G. Optimal administration frequency of cisplatin concurrently with radical radiotherapy in the definitive treatment of locally advanced, inoperable squamous cell cancer of the head and neck. Still obscured by clouds? Turk J Oncol 2019;34(2):133–6.
  • 2. Jeremic B, Ozyigit G, Dubinsky P, Filipovic N. Importance of hpv positivity in squamous cell head and neck cancer. Turk J Oncol 2019;34(3):204–14.
  • 3. Troost EG, Schinagl DA, Bussink J, Boermano C, van der Kogel AJ, Oyen WJ, et al. Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med 2010;51(1):66–76.
  • 4. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia induced treatment resistance. Radiother Oncol 2011;101(3):369–75.
  • 5. Chang JH, Wada M, Anderson NJ, Joon DL, Lee ST, Gong SJ, et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)FFMISO PET: a biological modeling study. Acta Oncol 2013;52(8):1723–9.
  • 6. Lee N, Schoder H, Beattie B, Lanning R, Riaz N, McBride S, et al. Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human Papillomavirusrelated oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2016;96(1):9–17.
  • 7. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 Trial. Radiother Oncol 2012;105(1):14–20.
  • 8. Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M, et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 2011;25(5):339–45.
  • 9. Grassi I, Nanni C, Cicoria G, Blasi C, Bunkheila F, Lopci E, et al. Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective study. Clin Nucl Med 2014;39(1):e59–63.
  • 10. Geets X, Daisne JF, Gregoire V, Hamoir M, Lonneux M. Role of 11-C methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG-PET and CT. Radiother Oncol 2004;71(3):267–73.
  • 11. Hasebe M, Yoshikawa K, Ohashi S, Toubaru S, Kawaguchi K, Sato J, et al. A study on the prognostic evaluation of carbon ion radiotherapy for head and neck adenocarcinoma with C-11 methionine PET. Mol Imaging Biol 2010;12(5):554–62.
  • 12. Buus S, Grau C, Munk OL, Bender D, Jensen K, Keiding S. 11C-Methionine PET, a novel method for measuring regional salivary gland function after radiotherapy of head and neck cancer. Radiother Oncol 2004;73(3):289–96.
  • 13. Buus S, Grau C, Munk OL, Rodell A, Jensen K, Mouridsen K, et al. Individual radiation response of parotid glands investigated by dynamic 11C-methionine PET. Radiother Oncol 2006;78(3):262–9.
  • 14. Hoeben BA, Troost EG, Span PN, van Herpen CM, Bussink J, Oyen WJ, et al. 18F-FLT PET during radio therapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med 2013;54(4):532–40.
  • 15. Hoshikawa H, Yamamoto Y, Mori T, Kishino T, Fukumura T, Samukawa Y, et al. Predictive value of suvbased parameters derived from pre-treatment (18)FFLT PET/CT for short-term outcome with head and neck cancers. Ann Nucl Med 2014;28(10):1020–6.
  • 16. Arens AI, Troost EG, Hoeben BA, Grootjans W, Lee JA, Grégoire V, et al. Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. Eur J Nucl Med Mol Imaging 2014;41(5):915–24.
  • 17. Kubiessa K, Purz S, Gawlitza M, Kühn A, Fuchs J, Steinhoff KG, et al. Initial clinical results of simultaneous 18F-FDG PET/MRI in comparison to 18F-FDG PET/CT in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 2014;41(4):639–48.
  • 18. Samołyk-Kogaczewska N, Sierko E, Zuzda K, Gugnacki P, Szumowski P, Mojsak M, et al. PET/MRIguided GTV delineation during radiotherapy planning in patients with squamous cell carcinoma of the tongue. Strahlenther Onkol 2019;195(9):780–91.
  • 19. Leibfarth S, Mönnich D, Welz S, Siegel C, Schwenzer N, Schmidt H, et al. A strategy for multimodal deformable image registration to integrate PET/MR into radiotherapy treatment planning. Acta Oncol 2013;52(7):1353–9.
  • 20. Winter RM, Leibfarth S, Schmidt H, Zwirner K, Mönnich D, Welz S, et al. Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients. Radiother Oncol 2018;128(3):485–91.
  • 21. Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003;55(2):312–21.
  • 22. Chao KS, Ozyigit G, Blanco AI, Thorstad WL, Deasy JO, Haughey BH, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004;59(1):43–50.
  • 23. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006;24(17):2618–23.
  • 24. Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 2009;74(1):1–8.
  • 25. Marta GN, Silva V, de Andrade Carvalho H, de Arruda FF, Hanna SA, Gadia R, et al. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol 2014;110(1):9–15.
  • 26. Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001;61(2):275–80.
  • 27. Beadle BM, Liao KP, Elting LS, Buchholz TA, Ang KK, Garden AS, et al. Improved survival using intensitymodulated radiation therapy in head and neck cancers: a SEER-medicare analysis. Cancer 2014;120(5):702–10. 28. Studer G, Zwahlen RA, Graetz KW, Davis BJ, Glanzmann C. IMRT in oral cavity cancer. Radiat Oncol 2007;2:16.
  • 29. Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y. Intensity- modulated radiation therapy versus 2D-RT or 3DCRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral Oncol 2015;51(11):1041–6.
  • 30. Gupta T, Kannan S, Ghosh-Laskar S, Agarwal JP. Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma. PLoS One 2018;13(7):e0200137.
  • 31. Ozyigit G, Chao KS. Clinical experience of headand- neck cancer IMRT with serial tomotherapy. Med Dosim 2002;27(2):91–8.
  • 32. Jiang L, Zhang Y, Yang Z, Liang F, Wu J, Wang R. A comparison of clinical outcomes between simultaneous integrated boost (SIB) versus sequential boost (SEQ) intensity modulated radiation therapy (IMRT) for head and neck cancer: a meta-analysis. Medicine (Baltimore) 2019;34:e16942.
  • 33. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardization difficult. Acta Oncol 2009; 48(3):431–9.
  • 34. Spiotto MT, Weichselbaum RR. comparison of 3D conformal radiotherapy and intensity modulated radiotherapy with or without simultaneous integrated boost during concurrent chemoradiation for locally advanced head and neck cancers. PLoS One 2014;9:e94456.
  • 35. Vlacich G, Stavas MJ, Pendyala P, Chen SC, Shyr Y, Cmelak AJ. A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer. Radiat Oncol 2017;12(1):13.
  • 36. Vanetti E, Clivio A, Nicolini G, Fogliata A, Ghosh- Laskar S, Agarwal JP, et al. Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: a treatment planning comparison with fixed field IMRT. Radiother Oncol 2009;92(1):111–7.
  • 37. Matsuzak MM, Yan D, Grills I, Martinez A. Clinical applications of volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2010;77(2):608–16.
  • 38. Bertelsen A, Hansen CR, Johansen J, Brink C. Single arc volumetric modulated arc therapy of head and neck cancer. Radiother Oncol 2010;95(2):142–8.
  • 39. Clemente S, Wu B, Sanguineti G, Fusco V, Ricchetti F, Wong J, et al. Smart arc-based volumetric modulated arc therapy for oropharyngeal cancer: a dosimetric comparison with both intensity-modulated radiation therapy and helical tomotherapy. Int J Radiat Oncol Biol Phys 2011;80(4):1248–55.
  • 40. Van Gestel D, van Vliet-Vroegindeweij C, Van den Heuvel F, Crijns W, Coelmont A, De Ost B, et al. RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. Radiat Oncol 2013;8:37.
  • 41. Chang SD, Tate DJ, Goffinet DR, Martin DP, Adler JR Jr. Treatment of nasopharyngeal carcinoma: stereotactic radiosurgery boost following fractionated radiotherapy. Stereotact Funct Neurosurg 1999;73(1-4):64–7.
  • 42. Ahn YC, Lee CK, Kin DY, Huh SJ, Yeo IH, Lim DH, et al. Fractionated stereotactic radiation therapy for extracranial head and neck tumors. Int J Radiat Oncol Biol Phys 2000;48(2):501–5.
  • 43. Siddiqui F, Patel M, Khan M, McLean S, Dragovic J, Jin JY, et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009;74(4):1047–53.
  • 44. Kodani N, Yamazaki H, Tsubokura T, Shiomi H, Kobayashi K, Nishimura T, et al. Stereotactic body radiation therapy for head and neck tumor: disease control and morbidity outcomes. J Radiat Res 2011;52(1):24–31.
  • 45. Baker S, Verduijn G, Petit S, Nuyttens JJ, Sewnaik A, van der Lugt A, et al. Locoregional failures and their relation to radiation fields following stereotactic body radiotherapy boost for oropharyngeal squamous cell carcinoma. Head Neck 2019;41(6):1622–31.
  • 46. Díaz-Martínez JA, Esquenazi Y, Martir M, Citardi MJ, Karni RJ, Blanco AI. Planned gamma knife boost after chemoradiotherapy for selected sinonasal and nasopharyngeal cancers.
  • 47. Ozyigit G, Cengiz M, Hurmuz P, Yazici G, Gultekin M, Akyol F, et al. Robotic stereotactic radiosurgery in patients with nasal cavity and paranasal sinus tumors. Technol Cancer Res Treat 2014;13(5):409–13.
  • 48. Ho JC, Phan J. Reirradiation of head and neck cancer using modern highly conformal techniques. Head Neck 2018;40(9):2078–93.
  • 49. Ozyigit G, Cengiz M, Yazici G, Yildiz F, Gurkaynak M, Zorlu F, et al. A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2011;81(4):e263–8.
  • 50. Alterio D, Marvaso G, Ferrari A, Volpe S, Orecchia R, Jereczek-Fossa BA. Modern radiotherapy for head and neck cancer. Semin Oncol 2019;46(3):233–45.
  • 51. Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008;26(34):5518–23.
  • 52. Cengiz M, Özyiğit G, Yazici G, Doğan A, Yildiz F, Zorlu F, et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2011;81(1):104–9.
  • 53. Yazici G, Sanlı TY, Cengiz M, Yuce D, Gultekin M, Hurmuz P, et al. A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiaton for recurrent head and neck cancers. Radiat Oncol 2013;8:242.
  • 54. Oda K, Mori Y, Kobayashi T, Kida Y, Yokoi H, Shibamoto Y, et al. Stereotactic radiosurgery as a salvage treatment for recurrent epipharyngeal carcinoma. stereotact funct neurosurg 2006;84(2-3):103–8.
  • 55. Kohler RE, Sheets NC, Wheeler SB, Nutting C, Hall E, Chera BS. Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2013;87(4):683–9.
  • 56. Marta GN, Weltman E, Ferrigno R. Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis. Rev Assoc Bras 2018;64(4):318–23.
  • 57. Ikawa H, Koto M, Demizu Y, Saitoh JI, Suefuji H, Okimoto T, et al. Multicenter study of carbon-ion radiation therapy for nonsquamous cell carcinomas of the oral cavity. Cancer Med 2019;8(12):5482–91.
  • 58. Shirai K, Koto M, Demizu Y, Suefuji H, Ohno T, Tsuji H, et al. Multi-institutional retrospective study of mucoepidermoid carcinoma treated with carbon-ion radiotherapy. Cancer Sci 2017;108(7):1447–51.
  • 59. Held T, Windisch P, Akbaba S, Lang K, El Shafie R, Bernhardt D, et al. Carbon ion reirradiation for recurrent head and neck cancer: a single-institutional experience. Int J Radiat Oncol Biol Phys 2019;105(4):803–11.
  • 60. Akbaba S, Held T, Lang K, Forster T, Federspil P, Herfarth K, et al. Bimodal radiotherapy with active rasterscanning carbon ion radiotherapy and intensitymodulated radiotherapy in high-risk nasopharyngeal carcinoma results in excellent local control. Cancers (Basel) 2019;11(3):379.
  • 61. Akbaba S, Ahmed D, Lang K, Held T, Mattke M, Hoerner- Rieber J, et al. Results of a combination treatment with intensity modulated radiotherapy and active raster-scanning carbon ion boost for adenoid cystic carcinoma of the minor salivary glands of the nasopharynx. Oral Oncol 2019;91(1):39–46.
  • 62. Adeberg S, Akbaba S, Lang K, Held T, Verma V, Nikoghosyan A, et al. The phase 1/2 ACCEPT Trial: concurrent cetuximab and intensity-modulated radiotherapy with carbon ion boost for adenoid cystic carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2020;106(1):167–73.
  • 63. Jensen AD, Nikoghosyan AV, Lossner K, Haberer T, Jäkel O, Münter MW, et al. COSMIC: a regimen of intensity modulated radiation therapy plus dose-escalated, raster-scanned carbon ion boost for malignant salivary gland tumors: results of the prospective phase 2 trial. Int J Radiat Oncol Biol Phys 2015;93(1):37–46.
  • 64. Buchholz TA, Laramore GE, Griffin BW, Koh WJ, Griffin TW. The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms. Cancer 1992;69(11):2779–88.
  • 65. Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, et al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol 2001;59(2):161–7.
  • 66. Stannard C, Vernimmen F, Carrara H, Jones D, Fredericks S, Hille J, et al. Malignant salivary gland tumours: can fast neutron therapy results point the way to carbon ion therapy? Radiother Oncol 2013;109(2):262–8.
  • 67. Maor MH, Errington RD, Caplan RJ, Griffin TW, Laramore GE, Parker RG, et al. Fast-neutron therapy in advanced head and neck cancer: a collaborative international randomized trial. Int J Radiat Oncol Biol Phys 1995;32(3):599–604.
  • 68. van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. oncologist 2011;16(3):366–77.
  • 69. Lomax AJ, Goitein M, Adams J. Intensity modulation in radiotherapy: photons versus protons in the paranasal sinus. Radiother Oncol 2003;66(1):11–8.
  • 70. Widesott L, Pierelli A, Fiorino C, Dell’oca I, Broggi S, Cattaneo GM, et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys 2008;72(2):589–96.
  • 71. van der Laan HP, van de Water TA, van Herpt HE, Christianen ME, Bijl HP, Korevaar EW, et al. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: a planning comparative study. Acta Oncol 2013;52(3):561–9.
  • 72. Kandula S, Zhu X, Garden AS, Gillin M, Rosenthal DI, Ang KK, et al. Spot-scanning beam proton therapy vs. Intensity-modulated radiation therapy for ipsilateral head and neck malignancies: a treatment planning comparison. Med Dosim 2013;38(4):390–4.
  • 73. Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties. Phys Med Biol 2008;53(4):1027–42.
  • 74. Quan EM, Liu W, Wu R, Li Y, Frank SJ, Zhang X, et al. Preliminary evaluation of multifield and single field optimization for the treatment planning of spot-scanning proton therapy of head and neck cancer. Med Phys 2013;40(8):081709.
  • 75. Kraan AC, van de Water S, Teguh DN, Al-Mamgani A, Madden T, Kooy HM, et al. Dose uncertainties in IMPT for oropharyngeal cancer in the presence of anatomical, range, and setup errors. Int J Radiat Oncol Biol Phys 2013;87(5):888–96.
  • 76. Apinorasethkul O, Kirk M, Teo K, Swisher-McClure S, Lukens JN, Lin A. Pencil beam scanning proton therapy vs rotational arc radiation therapy: a treatment planning comparison for postoperative oropharyngeal cancer. Med Dosim 2017;42(1):7–11.
  • 77. Fukumitsu N, Okumura T, Mizumoto M, Oshiro Y, Hashimoto T, Kanemoto A, et al. Outcome of T4 (International Union Against Cancer Staging System, 7th edition) or recurrent nasal cavity and paranasal sinus carcinoma treated with proton beam. Int J Radiat Oncol Biol Phys 2012;83(2):704–11.
  • 78. Rutz HP, Weber DC, Goitein G, Ares C, Bolsi A, Lomax AJ, et al. Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcoma in children and adolescents: initial experience at Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 2008;71(1):220–25.
  • 79. Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long¬-term report. Int J Radiat Oncol Biol Phys 2009;75(4):1111–18.
  • 80. Chan A, Adams JA, Weyman E. A Phase II trial of proton radiation therapy with chemotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2012;84:S151–52.
  • 81. Holliday EB, Garden AS, Rosenthal DI, Fuller CD, Morrison WH, Gunn GB, et al. Proton therapy reduces treatment¬ related toxicities for patients with nasopharyngeal cancer: a case¬ match control study of intensity ¬modulated proton therapy and intensity ¬ modulated photon therapy. Int J Particle Ther 2015;2(1):19–28.
  • 82. McDonald MW, Liu Y, Moore MG, Johnstone PA. acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy. Radiat Oncol 2016;11:32.
  • 83. Truong MT, Kamat UR, Liebsch NJ, Curry WT, Lin DT, Barker FG 2nd, et al. Proton radiation therapy for primary sphenoid sinus malignancies: treatment outcome and prognostic factors. Head Neck 2009;31(10):1297–308.
  • 84. Russo AL, Adams JA, Weyman EA, Busse PM, Goldberg SI, Varvares M, et al. Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2016;95(1):368– 76.
  • 85. Dagan R, Bryant C, Li Z, Yeung D, Justice J, Dzieglewiski P, et al. Outcomes of sinonasal cancer treated with proton therapy. Int J Radiat Oncol Biol Phys 2016;95(1):377–85.
  • 86. Nakamura T, Azami Y, Ono T, Yamaguchi H, Hayashi Y, Suzuki M, et al. Preliminary results of proton beam therapy combined with weekly cisplatin intraarterial infusion via a superficial temporal artery for treatment of maxillary sinus carcinoma. Jpn J Clin Oncol 2016;46(1):46–50.
  • 87. El-Sawy T, Frank SJ, Hanna E, Sniegowski M, Lai SY, Nasser QJ, et al. Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas. Ophthal Plast Reconstr Surg 2013;29(6):454–7.
  • 88. Holliday EB, Esmaeli B, Pinckard J, Garden AS, Rosenthal DI, Morrison WH, et al. A Multidisciplinary orbitsparing treatment approach that includes proton therapy for epithelial tumors of the orbit and ocular adnexa. Int J Radiat Oncol Biol Phys 2016;95(1):344–52.
  • 89. Slater JD, Yonemoto LT, Mantik DW, Bush DA, Preston W, Grove RI, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University medical center using a concomitant boost technique. Int J Radiat Oncol Biol Phys 2005;62(2):494–500.
  • 90. Hutcheson K, Lewin JS, Garden AS. Early experience with IMPT for the treatment of oropharyngeal tumors: acute toxicities and swallowing-related outcomes. Int J Radiat Oncol Biol Phys 2013;87:S604.
  • 91. Blanchard P, Garden AS, Gunn GB, Rosenthal DI, Morrison WH, Hernandez M, et al. Intensity ¬modulated proton beam therapy (IMPT) versus intensity¬ modulated photon therapy (IMRT) for patients with oropharynx cancer a case matched analysis. Radiother Oncol 2016;120(1):48–55.
  • 92. Gunn GB, Blanchard P, Garden AS, Zhu XR, Fuller CD, Mohamed AS, et al. Clinical outcomes and patterns of disease recurrence after intensity modulated proton therapy for oropharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys 2016;95(1):360–7.
  • 93. Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, et al. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys 2016;95(1):386–95.
  • 94. Jeremic B, Ozyigit G, Jeremic M, Dubinsky P. Impacts of radiotherapy fractionation on outcome in squamous cell head and neck cancer (SQC HNC). Turk J Oncol 2020;35(3):356-62.
  • 95. Jeremic B, Dubinsky P, Jeremic M, Kiladze I, Ozyigit G. Optimal dose of cisplatin (CDDP) given concurrently with radiotherapy (RT) in locally advanced squamous cell head and neck cancer (SQC HNC). Turk J Oncol 2020;35(2):237–41.
APA Jeremic B, Kiladze I, ÖZYİĞİT G, Filipovic N, Dubinsky P (2021). Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. , 236 - 246. 10.5505/tjo.2020.2579
Chicago Jeremic Branislav,Kiladze Ivane,ÖZYİĞİT Gökhan,Filipovic Nenad,Dubinsky Pavol Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. (2021): 236 - 246. 10.5505/tjo.2020.2579
MLA Jeremic Branislav,Kiladze Ivane,ÖZYİĞİT Gökhan,Filipovic Nenad,Dubinsky Pavol Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. , 2021, ss.236 - 246. 10.5505/tjo.2020.2579
AMA Jeremic B,Kiladze I,ÖZYİĞİT G,Filipovic N,Dubinsky P Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. . 2021; 236 - 246. 10.5505/tjo.2020.2579
Vancouver Jeremic B,Kiladze I,ÖZYİĞİT G,Filipovic N,Dubinsky P Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. . 2021; 236 - 246. 10.5505/tjo.2020.2579
IEEE Jeremic B,Kiladze I,ÖZYİĞİT G,Filipovic N,Dubinsky P "Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer." , ss.236 - 246, 2021. 10.5505/tjo.2020.2579
ISNAD Jeremic, Branislav vd. "Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer". (2021), 236-246. https://doi.org/10.5505/tjo.2020.2579
APA Jeremic B, Kiladze I, ÖZYİĞİT G, Filipovic N, Dubinsky P (2021). Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. Türk Onkoloji Dergisi, 36(2), 236 - 246. 10.5505/tjo.2020.2579
Chicago Jeremic Branislav,Kiladze Ivane,ÖZYİĞİT Gökhan,Filipovic Nenad,Dubinsky Pavol Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. Türk Onkoloji Dergisi 36, no.2 (2021): 236 - 246. 10.5505/tjo.2020.2579
MLA Jeremic Branislav,Kiladze Ivane,ÖZYİĞİT Gökhan,Filipovic Nenad,Dubinsky Pavol Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. Türk Onkoloji Dergisi, vol.36, no.2, 2021, ss.236 - 246. 10.5505/tjo.2020.2579
AMA Jeremic B,Kiladze I,ÖZYİĞİT G,Filipovic N,Dubinsky P Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. Türk Onkoloji Dergisi. 2021; 36(2): 236 - 246. 10.5505/tjo.2020.2579
Vancouver Jeremic B,Kiladze I,ÖZYİĞİT G,Filipovic N,Dubinsky P Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer. Türk Onkoloji Dergisi. 2021; 36(2): 236 - 246. 10.5505/tjo.2020.2579
IEEE Jeremic B,Kiladze I,ÖZYİĞİT G,Filipovic N,Dubinsky P "Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer." Türk Onkoloji Dergisi, 36, ss.236 - 246, 2021. 10.5505/tjo.2020.2579
ISNAD Jeremic, Branislav vd. "Novel Technological Aspects of Radiation Therapy in Head and Neck Cancer". Türk Onkoloji Dergisi 36/2 (2021), 236-246. https://doi.org/10.5505/tjo.2020.2579